Global Autologous Biologics 麻豆原创 Research Report 2025

Publication ID:

PB503254439

Publication Date:

March 4, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

The global market for Autologous Biologics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Autologous Biologics is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Autologous Biologics is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Autologous Biologics include Vericel Corporation, BioTime, Inc., Pharmicell Co., BrainStorm Cell Therapeutics, Opexa Therapeutics, Inc, Pharmicell Co., Inc, Neostem, Dendreon Corporation, Regenexx, Cytori Therapeutics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Autologous Biologics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Autologous Biologics.
The Autologous Biologics market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Autologous Biologics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Autologous Biologics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Vericel Corporation
BioTime, Inc.
Pharmicell Co.
BrainStorm Cell Therapeutics
Opexa Therapeutics, Inc
Pharmicell Co., Inc
Neostem
Dendreon Corporation
Regenexx
Cytori Therapeutics
Segment by Type
Adipose Tissue
Plasma
Others
Segment by Application
Hospitals
Ambulatory Centers
Research Centers
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Autologous Biologics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Autologous Biologics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Autologous Biologics 麻豆原创 Overview
1.1 Product Definition
1.2 Autologous Biologics by Type
1.2.1 Global Autologous Biologics 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 Adipose Tissue
1.2.3 Plasma
1.2.4 Others
1.3 Autologous Biologics by Application
1.3.1 Global Autologous Biologics 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Ambulatory Centers
1.3.4 Research Centers
1.4 Global Autologous Biologics 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Autologous Biologics Revenue 2020-2031
1.4.2 Global Autologous Biologics Sales 2020-2031
1.4.3 Global Autologous Biologics 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Autologous Biologics 麻豆原创 Competition by Manufacturers
2.1 Global Autologous Biologics Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Autologous Biologics Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Autologous Biologics Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Autologous Biologics, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Autologous Biologics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Autologous Biologics, Product Type & Application
2.7 Global Key Manufacturers of Autologous Biologics, Date of Enter into This Industry
2.8 Global Autologous Biologics 麻豆原创 Competitive Situation and Trends
2.8.1 Global Autologous Biologics 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Autologous Biologics Players 麻豆原创 Share by Revenue
2.8.3 Global Autologous Biologics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Autologous Biologics 麻豆原创 Scenario by Region
3.1 Global Autologous Biologics 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Autologous Biologics Sales by Region: 2020-2031
3.2.1 Global Autologous Biologics Sales by Region: 2020-2025
3.2.2 Global Autologous Biologics Sales by Region: 2026-2031
3.3 Global Autologous Biologics Revenue by Region: 2020-2031
3.3.1 Global Autologous Biologics Revenue by Region: 2020-2025
3.3.2 Global Autologous Biologics Revenue by Region: 2026-2031
3.4 North America Autologous Biologics 麻豆原创 Facts & Figures by Country
3.4.1 North America Autologous Biologics 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Autologous Biologics Sales by Country (2020-2031)
3.4.3 North America Autologous Biologics Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Autologous Biologics 麻豆原创 Facts & Figures by Country
3.5.1 Europe Autologous Biologics 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Autologous Biologics Sales by Country (2020-2031)
3.5.3 Europe Autologous Biologics Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Autologous Biologics 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Autologous Biologics 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Autologous Biologics Sales by Region (2020-2031)
3.6.3 Asia Pacific Autologous Biologics Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Autologous Biologics 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Autologous Biologics 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Autologous Biologics Sales by Country (2020-2031)
3.7.3 Latin America Autologous Biologics Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Autologous Biologics 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Autologous Biologics 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Autologous Biologics Sales by Country (2020-2031)
3.8.3 Middle East and Africa Autologous Biologics Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Autologous Biologics Sales by Type (2020-2031)
4.1.1 Global Autologous Biologics Sales by Type (2020-2025)
4.1.2 Global Autologous Biologics Sales by Type (2026-2031)
4.1.3 Global Autologous Biologics Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Autologous Biologics Revenue by Type (2020-2031)
4.2.1 Global Autologous Biologics Revenue by Type (2020-2025)
4.2.2 Global Autologous Biologics Revenue by Type (2026-2031)
4.2.3 Global Autologous Biologics Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Autologous Biologics Price by Type (2020-2031)
5 Segment by Application
5.1 Global Autologous Biologics Sales by Application (2020-2031)
5.1.1 Global Autologous Biologics Sales by Application (2020-2025)
5.1.2 Global Autologous Biologics Sales by Application (2026-2031)
5.1.3 Global Autologous Biologics Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Autologous Biologics Revenue by Application (2020-2031)
5.2.1 Global Autologous Biologics Revenue by Application (2020-2025)
5.2.2 Global Autologous Biologics Revenue by Application (2026-2031)
5.2.3 Global Autologous Biologics Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Autologous Biologics Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Vericel Corporation
6.1.1 Vericel Corporation Company Information
6.1.2 Vericel Corporation Description and Business Overview
6.1.3 Vericel Corporation Autologous Biologics Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Vericel Corporation Autologous Biologics Product Portfolio
6.1.5 Vericel Corporation Recent Developments/Updates
6.2 BioTime, Inc.
6.2.1 BioTime, Inc. Company Information
6.2.2 BioTime, Inc. Description and Business Overview
6.2.3 BioTime, Inc. Autologous Biologics Sales, Revenue and Gross Margin (2020-2025)
6.2.4 BioTime, Inc. Autologous Biologics Product Portfolio
6.2.5 BioTime, Inc. Recent Developments/Updates
6.3 Pharmicell Co.
6.3.1 Pharmicell Co. Company Information
6.3.2 Pharmicell Co. Description and Business Overview
6.3.3 Pharmicell Co. Autologous Biologics Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pharmicell Co. Autologous Biologics Product Portfolio
6.3.5 Pharmicell Co. Recent Developments/Updates
6.4 BrainStorm Cell Therapeutics
6.4.1 BrainStorm Cell Therapeutics Company Information
6.4.2 BrainStorm Cell Therapeutics Description and Business Overview
6.4.3 BrainStorm Cell Therapeutics Autologous Biologics Sales, Revenue and Gross Margin (2020-2025)
6.4.4 BrainStorm Cell Therapeutics Autologous Biologics Product Portfolio
6.4.5 BrainStorm Cell Therapeutics Recent Developments/Updates
6.5 Opexa Therapeutics, Inc
6.5.1 Opexa Therapeutics, Inc Company Information
6.5.2 Opexa Therapeutics, Inc Description and Business Overview
6.5.3 Opexa Therapeutics, Inc Autologous Biologics Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Opexa Therapeutics, Inc Autologous Biologics Product Portfolio
6.5.5 Opexa Therapeutics, Inc Recent Developments/Updates
6.6 Pharmicell Co., Inc
6.6.1 Pharmicell Co., Inc Company Information
6.6.2 Pharmicell Co., Inc Description and Business Overview
6.6.3 Pharmicell Co., Inc Autologous Biologics Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Pharmicell Co., Inc Autologous Biologics Product Portfolio
6.6.5 Pharmicell Co., Inc Recent Developments/Updates
6.7 Neostem
6.7.1 Neostem Company Information
6.7.2 Neostem Description and Business Overview
6.7.3 Neostem Autologous Biologics Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Neostem Autologous Biologics Product Portfolio
6.7.5 Neostem Recent Developments/Updates
6.8 Dendreon Corporation
6.8.1 Dendreon Corporation Company Information
6.8.2 Dendreon Corporation Description and Business Overview
6.8.3 Dendreon Corporation Autologous Biologics Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Dendreon Corporation Autologous Biologics Product Portfolio
6.8.5 Dendreon Corporation Recent Developments/Updates
6.9 Regenexx
6.9.1 Regenexx Company Information
6.9.2 Regenexx Description and Business Overview
6.9.3 Regenexx Autologous Biologics Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Regenexx Autologous Biologics Product Portfolio
6.9.5 Regenexx Recent Developments/Updates
6.10 Cytori Therapeutics
6.10.1 Cytori Therapeutics Company Information
6.10.2 Cytori Therapeutics Description and Business Overview
6.10.3 Cytori Therapeutics Autologous Biologics Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Cytori Therapeutics Autologous Biologics Product Portfolio
6.10.5 Cytori Therapeutics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Autologous Biologics Industry Chain Analysis
7.2 Autologous Biologics Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Autologous Biologics Production Mode & Process Analysis
7.4 Autologous Biologics Sales and 麻豆原创ing
7.4.1 Autologous Biologics Sales Channels
7.4.2 Autologous Biologics Distributors
7.5 Autologous Biologics Customer Analysis
8 Autologous Biologics 麻豆原创 Dynamics
8.1 Autologous Biologics Industry Trends
8.2 Autologous Biologics 麻豆原创 Drivers
8.3 Autologous Biologics 麻豆原创 Challenges
8.4 Autologous Biologics 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Vericel Corporation
BioTime, Inc.
Pharmicell Co.
BrainStorm Cell Therapeutics
Opexa Therapeutics, Inc
Pharmicell Co., Inc
Neostem
Dendreon Corporation
Regenexx
Cytori Therapeutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.